{"disease":{"id":"philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-ph-all","name":"philadelphia chromosome positive acute lymphoblastic leukemia ph all"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03589326","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07493408","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03595917","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Marlise Luskin, MD","has_results":false},{"nct_id":"NCT01667133","title":"A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":true},{"nct_id":"NCT04501614","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01592136","title":"Expanded Access Program of Ponatinib","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}